🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Mario Gabelli’s CPRX Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+14,000 Shares
Current Position
14,000 Shares
$440,020 Value

Mario Gabelli's CPRX Position Overview

Mario Gabelli (via Gamco Investors, Inc. Et Al) currently holds 14,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $440,020, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Mario Gabelli has initiated a new position in CPRX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Mario Gabelli's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Mario Gabelli

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +14,000 New Buy 14,000 $31.43

Mario Gabelli's Catalyst Pharmaceuticals Investment FAQs

Mario Gabelli first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q2 2026, acquiring 14,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Mario Gabelli has held Catalyst Pharmaceuticals, Inc. (CPRX) for 1 quarters since Q2 2026.

Mario Gabelli's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q2 2026, adding 14,000 shares worth $440,020.

According to the latest 13F filing for Q2 2026, Mario Gabelli's firm, Gamco Investors, Inc. Et Al, owns 14,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $440,020.

As of the Q2 2026 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.00% of Mario Gabelli's publicly disclosed stock portfolio, making it one of their key holdings.

Mario Gabelli's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 14,000 shares, as reported at the end of Q2 2026.